B. Riley Securities Maintains Buy on Intercept Pharma, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani maintains a Buy rating on Intercept Pharma (NASDAQ:ICPT) but lowers the price target from $30 to $15.
May 30, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B. Riley Securities maintains a Buy rating on Intercept Pharma (NASDAQ:ICPT) but lowers the price target from $30 to $15.
The news of B. Riley Securities maintaining a Buy rating on Intercept Pharma indicates a positive outlook for the company. However, the lowering of the price target from $30 to $15 suggests that the analyst has revised expectations for the stock's performance. This mixed signal may result in a neutral short-term impact on ICPT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100